Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2.

OBJECTIVES Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2. The ABCC2 rs717620 A allele has been associated with enterohepatic recirculation of MPA, and our previous work had correlated the discontinuance of MPA with this allele in pediatric heart transplant patients. Therefore, we hypothesized that the ABCC2 rs717620 A allele would be associated with poorer outcomes including rejection with hemodynamic compromise (RHC), graft failure, and death in the pediatric heart transplant (PHTx) population receiving MPA. METHODS PHTx recipients from 6 institutions in the Pediatric Heart Transplantation Study (PHTS) from the period of 1993-2009, receiving MPA therapy, were genotyped for ABCC2 rs717620. Genotyping was accomplished by direct sequencing. Demographic and outcome data were limited to the data routinely collected as part of the PHTS and included RHC and mortality. RESULTS Two hundred ninety patients were identified who received MPA at some point post transplantation, of which 200 carried the GG genotype, 81 carried the AG genotype, and 9 carried the AA genotype. Follow-up time after transplantation was 6 years. RHC occurred in 76 patients and 18 patients died. In the 281 patients followed up more than 1 year, late RHC (>1 year post transplantation) occurred in 42 patients. While both RHC and late RHC were associated with the ABCC2 rs717620 GG genotype (hazard ratios: 1.80 and 4.57, respectively, p<0.05) in all patients, this association was not significant in PHTx patients receiving only MPA as the antiproliferative agent from the time of transplant (n=142). CONCLUSIONS ABCC2 rs717620 polymorphisms varied within racial groups. As a candidate gene assessment, the ABCC2 rs717620 AG and AA genotypes may be associated with improved, rather than poorer, RHC in PHTx patients receiving MPA therapy. ABCC2 rs717620 polymorphisms should be included in any expanded pharmacogenomic analysis of outcomes after pediatric heart transplantation.

[1]  D. Bernstein,et al.  Gene Polymorphisms Impact the Risk of Rejection With Hemodynamic Compromise: A Multicenter Study , 2011, Transplantation.

[2]  Jie Zheng,et al.  Rejection with hemodynamic compromise in the current era of pediatric heart transplantation: a multi-institutional study. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  S. Webber,et al.  Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Jie Zheng,et al.  Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  D. Min,et al.  Genetic Polymorphisms of MRP2 and UGT2B7 and Gastrointestinal Symptoms in Renal Transplant Recipients Taking Mycophenolic Acid , 2009, Therapeutic drug monitoring.

[6]  A. Hartmann,et al.  UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients , 2009, Clinical pharmacology and therapeutics.

[7]  L. Essioux,et al.  Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism , 2009, Pharmacogenetics and genomics.

[8]  D. Dunkler,et al.  Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[9]  D. Bernstein,et al.  Genetic Polymorphisms Impact the Risk of Acute Rejection in Pediatric Heart Transplantation: A Multi-Institutional Study , 2008, Transplantation.

[10]  V. Pravica,et al.  IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients , 2008, Clinical pharmacology and therapeutics.

[11]  V. Rao,et al.  Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  N. Perico,et al.  C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. , 2007, Pharmacogenomics.

[13]  T. Habuchi,et al.  Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients , 2007, European Journal of Clinical Pharmacology.

[14]  S. Webber,et al.  A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity , 2007, Pharmacogenetics and genomics.

[15]  D. Bernstein,et al.  Disparate Distribution of 16 Candidate Single Nucleotide Polymorphisms Among Racial and Ethnic Groups of Pediatric Heart Transplant Patients , 2006, Transplantation.

[16]  K. Verbeke,et al.  Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients , 2006, Transplantation.

[17]  M. Schnitzler,et al.  Mycophenolate Mofetil Dose Reductions and Discontinuations after Gastrointestinal Complications Are Associated with Renal Transplant Graft Failure , 2006, Transplantation.

[18]  C. Canter,et al.  Lessons learned from the pediatric heart transplant study. , 2006, Congenital heart disease.

[19]  R. Morris,et al.  ROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE , 2006, Drug Metabolism and Disposition.

[20]  M. Isola,et al.  Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. , 2005, Transplantation proceedings.

[21]  W. Weimar,et al.  Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance‐Associated Protein 2 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  O. Fardel,et al.  Physiological, pharmacological and clinical features of the multidrug resistance protein 2. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  D. Bernstein,et al.  Risk factors for recurrent rejection in pediatric heart transplantation: a multicenter experience. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  A. Daly.  Candidate gene case-control studies. , 2003, Pharmacogenomics.

[25]  P. Sapra,et al.  Cancer chemotherapy and heterocyclic compounds. , 2002, Current medicinal chemistry.

[26]  V. Armstrong,et al.  Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report , 2001, Therapeutic drug monitoring.

[27]  C. Canter,et al.  Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: a multi-institutional study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  C. Canter,et al.  Survival and risk factors for death after cardiac transplantation in infants. A multi-institutional study. The Pediatric Heart Transplant Study. , 1996, Circulation.